Physicochemical Properties
| CAS # | 2870703-21-0 |
| Appearance | Typically exists as solid at room temperature |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | COX-2 Bax Bcl-2 |
| ln Vitro | In A549 cells, antitumor agent-77 (compound 2a) (30 μM; 4 h) shows better cellular uptake and solubility than carboplatin[1]. Antitumor agent-77 (20 μM; 36 h) causes cytotoxicity by causing A549 cancer cells to undergo apoptosis[1]. Antitumor agent-77 (20 μM; 24 h) significantly down-regulates Bcl-2 and up-regulates Bax, along with increasing E-cadherin and decreasing vimentin[1]. Cell cycle arrest at S phase and G2/M phase is caused by antitumor agent-77 (20 μM; 24 h)[1]. Cell migration is inhibited by antitumor agent-77 (10 μM; 12 h) at a 52% inhibition rate[1]. |
| ln Vivo | Compound 2a, also known as antitumor agent-77, (6 μg/kg; intravenous; administered on days 8, 10, and 12) shows comparable potency to oxaliplatin, but without causing appreciable weight loss or kidney or liver damage[1]. |
| Cell Assay |
Apoptosis Analysis[1] Cell Types: A549 cells Tested Concentrations: 20 μM Incubation Duration: 36 hrs (hours) Experimental Results: Resulte cell apopsotsis with average apoptotic values (including both early and late apoptotic states which were displayed in Q1-LR and Q1-UR, respectively) of 25.34%. Western Blot Analysis[1] Cell Types: A549 cells Tested Concentrations: 20 μM Incubation Duration: 24 hrs (hours) Experimental Results: Elevated the level of cleaved caspase-3 and diminished the level of caspase-3 in A549 cells. diminished anti-apoptotic protein Bcl-2 and increased pro-apoptotic protein Bax. Elevated the expression of E-cadherin and on the other hand, lowered the protein level of Vimentin. Cell Cycle Analysis[1] Cell Types: A549 cells Tested Concentrations: 20 μM Incubation Duration: 24 hrs (hours) Experimental Results: Blocked Cell cycle progression in S and G2/M phase with the values of 41.11% and 26.03%, respectively. |
| Animal Protocol |
Animal/Disease Models: A549 xenograft models in mouse[1] Doses: 6 μg/kg Route of Administration: intravenous (iv) injection; administration on day 8, 10, 12 after establishing xenograft models (A549 cells; sc) Experimental Results: Dramatically repressed tumor growth, and maintained normal kidney and liver architecture in mice. |
| References |
[1]. Design and biological features of platinum (II) complexes with 3-hydroxy-3-(Trifluoromethyl)cyclobutane-1,1-Dicarboxylate as a leaving ligand. Eur J Med Chem. 2022 Nov 15;242:114673. |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |